文献速递肿瘤 PET/CT

68Ga-PSMA PET/CT联合多参数MRI提高临床显著性前列腺癌检出

Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis.
PubMed 文献 · J Nucl Med · 2018-12-14

该回顾性研究纳入54例根治性前列腺切除术前接受MRI和68Ga-PSMA PET/CT的患者,分析90个病灶(66个为临床显著性前列腺癌)。结果显示PET/MRI联合较单独MRI提高检出临床显著性前列腺癌的AUC(差值0.06,95%CI 0.01-0.12,P<0.05),灵敏度89% vs 76%(P<0.01),特异度无显著牺牲(96% vs 88%,P>0.05),对PI-RADS 3病灶改善明显(NRI 66.7%,P<0.01)。

要点

  • PET/MRI联合较MRI提高临床显著性前列腺癌检出(AUC差值0.06,P<0.05)。
  • PET/MRI灵敏度89% vs 76%(P<0.01),特异度96% vs 88%(P>0.05)。
  • PI-RADS 3病灶获益最明显(NRI 66.7%,P<0.01)。

核心结论

  • 68Ga-PSMA PET/CT联合多参数MRI可改善临床显著性前列腺癌的检出,尤其对PI-RADS 3病灶。

研究设计与样本

  • 回顾性纳入54例根治性前列腺切除术前接受MRI和68Ga-PSMA PET/CT的患者。
  • 共分析90个病灶,其中66个为临床显著性前列腺癌。

主要发现

  • PET/MRI较MRI检出临床显著性前列腺癌的AUC提高0.06(95%CI 0.01-0.12,P<0.05)。
  • PET/MRI较MRI的NRI为21.9%(P<0.01)。
  • 灵敏度89% vs 76%(P<0.01),特异度96% vs 88%(P>0.05)。
  • PI-RADS 3病灶的NRI为66.7%(P<0.01)。

临床怎么用

  • 对于PI-RADS 3病灶,可考虑联合68Ga-PSMA PET/CT与多参数MRI以提高临床显著性前列腺癌检出。

局限性

  • 回顾性研究,样本量54例,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to explore whether 68Ga-PSMA PET/CT alone (PET/CT) or in combination with multiparametric MRI (PET/MRI) can improve the detection of clinically significant prostate cancer (PCa). Methods: We retrospectively enrolled 54 patients who underwent both MRI and PET/CT before radical prostatectomy. Regions of interest on MR images, PET/CT images, and pathologic images were marked. A lesion was defined as a region of interest marked on images obtained with any of the 3 modalities. All lesions were characterized using the prostate imaging reporting and data system (PI-RADS), the molecular imaging PSMA expression score, and the pathologic results and analyzed. Diagnostic performance was analyzed by receiver-operating-characteristic analysis. Specific improvement for lesions with different PI-RADS scores was analyzed using the net reclassification index (NRI). Results: In total, 90 lesions from 54 patients were analyzed, among which 66 lesions represented clinically significant PCa. Receiver-operating-characteristic analysis showed PET/MRI to perform better than MRI in detecting clinically significant PCa (change in area under the curve, 0.06; 95% confidence interval, 0.01-0.12; P < 0.05). With the calculated cutoff, PET/MRI performed significantly better than MRI (NRI, 21.9%; P < 0.01), with an improvement in sensitivity (89% vs. 76%, P < 0.01) at no sacrifice of specificity (96% vs. 88%, P > 0.05). Improvement in diagnosing clinically significant PCa occurred for lesions classified as PI-RADS 3 (NRI, 66.7%; P < 0.01). Conclusion: PET/MRI improves the detection of clinically significant PCa for PI-RADS 3 lesions.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chen M, Zhang Q, Zhang C, et al. Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis. J Nucl Med. 2018. PMID: 30552201. doi:10.2967/jnumed.118.221010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。